Immutep Under Legal Investigation After TACTI-004 Phase III Study Halted

Immutep Faces Legal Scrutiny After Phase III Study Termination

Immutep Ltd. is currently under investigation by the Rosen Law Firm, a leading global entity specializing in investor rights, over allegations of disseminating misleading business information. This legal scrutiny follows a substantial announcement made on March 13, 2026, regarding the disruption of the TACTI-004 Phase III study involving Immutep's investigational drug, eftilagimod alfa (efti), which targets non-small cell lung cancer. The Independent Data Monitoring Committee (IDMC) recommended the discontinuation of the study due to concerns related to futility, a decision that has significant implications for both clinical progress and investor confidence in the company.

The abrupt halt of the TACTI-004 trial marks a critical juncture for Immutep, as it not only reflects challenges in the drug's efficacy but also raises questions about the company's communication with shareholders leading up to this decision. The market responded sharply to the news, causing the company's American Depositary Receipt (ADR) to plunge by 82.6%, resulting in a close of $0.48 per ADR. This drastic decline underscores the potential ramifications of the IDMC’s findings and suggests that investors may feel misled about the trial’s trajectory and the overall viability of eftilagimod alfa as a treatment for lung cancer.

Rosen Law Firm's investigation aims to uncover whether Immutep provided inaccurate disclosures that could have influenced investment decisions by stakeholders. The firm has a notable history in securities litigation, having successfully secured substantial settlements for affected investors, including the largest-ever case against a Chinese company. This focus on investor rights signifies not only the seriousness of the allegations against Immutep but also highlights the need for accountability in the biotech industry, where clinical trial outcomes often have a profound impact on investor confidence and market fluctuations.

In ancillary developments, investors who feel affected by the situation can participate in a potential class-action lawsuit with no upfront costs. Rosen Law Firm offers a contingency fee arrangement, encouraging shareholders to come forward and seek compensation for their losses. Legal counsel is crucial in navigating this complex legal landscape, and Rosen's history of excellence in the field positions them as a formidable advocate for affected investors.

As the investigation unfolds, it remains essential for stakeholders to stay informed about further developments and implications for Immutep and its future in the pharmaceutical industry. Such legal inquiries not only affect company operations but also reflect broader ethical considerations in drug development and corporate communication practices. Investors are advised to monitor updates closely as more information becomes available.